Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Clinton Drug Price Board, 23 Years Later

Executive Summary

Hillary Clinton is reviving an idea she first endorsed in 1993: a drug price oversight board, but the focus has changed. While the pharma industry isn’t about to embrace any federal oversight board, the new Clinton plan is a lot less threatening than the old one.


Related Content

Dems' 'Better Deal' Would Create Drug Price Gouging 'Enforcer'
Pricing Transparency Policies Not Suited To Generics, GPhA Argues
Formalizing 'Name And Shame': New Strategy To Rein In Price Increases
Big Pharma’s Unlikely Price Pledge Leader
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Clinton's Plan To Tame 'Unjustified' Drug Prices: Who's At Risk?


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts